MedTrace Logo

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

NCT00785629 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2012-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.

Conditions

Interventions

DRUG

Calcium acetate

DRUG

Lanthanum Carbonate

DRUG

Sevelamer Carbonate

DRUG

Placebo

Sponsors & Collaborators

  • Shire

    collaborator INDUSTRY

  • Fresenius Medical Care North America

    collaborator INDUSTRY

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • DaVita, Inc.

    collaborator INDUSTRY

  • Denver Nephrologists, P.C.

    lead OTHER

Principal Investigators

  • Geoffrey A Block, MD · Denver Nephrologists, PC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785629 on ClinicalTrials.gov